Research programme: vaccine therapeutics - Liquidia Technologies

Drug Profile

Research programme: vaccine therapeutics - Liquidia Technologies

Alternative Names: Multivalent PRINT nanoparticle pneumococcal vaccine - Liquidia Technologies

Latest Information Update: 14 Mar 2014

Price : $50

At a glance

  • Originator Liquidia Technologies
  • Developer Liquidia Technologies; Malaria Vaccine Initiative; PATH
  • Class Bacterial vaccines; Cancer vaccines; Influenza virus vaccines; Pneumococcal vaccines; Synthetic vaccines; Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Infections; Influenza virus infections; Pneumococcal infections
  • Research Malaria

Most Recent Events

  • 11 Mar 2014 Preclinical development is ongoing for Pneumococcal infections (prevention) in USA
  • 21 May 2013 Liquidia Technologies and PATH extend their collaborative agreement
  • 13 Dec 2011 Liquidia Technologies collaborates with PATH to develop next generation Pneumococcal vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top